Granules India net profit up 34 percent to Rs 111.4 crore in Q1
"This is the result of operational excellence and a vigilant watch over our margins through optimization of the product mix and by increased capacities and optimal capacity utilisation," Granules India Chairman and MD Krishna Prasad Chigurupati said.
New Delhi: Drug firm Granules India on Friday reported a 33.87 percent rise in its consolidated net profit to Rs 111.44 crore for the quarter ended June 30, 2020, mainly on account of robust sales.
The company had posted a net profit of Rs 83.24 crore for the corresponding period of the previous financial year, Granules India said in a filing to the BSE.
Its consolidated revenue from operations stood at Rs 735.59 crore for the quarter under consideration. It was Rs 595.27 crore for the same period a year ago, it added.
"This is the result of operational excellence and a vigilant watch over our margins through optimization of the product mix and by increased capacities and optimal capacity utilisation," Granules India Chairman and MD Krishna Prasad Chigurupati said.
The company also declared its first interim dividend of 25 paise per share of face value of Re 1 each representing 25 percent of paid-up capital for the financial year 2020-21, Granules India said.
Shares of Granules India Ltd were trading at Rs 253.90 per scrip on the BSE, up 3.23 percent from its previous close.
Read also: Granules Pharma recalls Metformin Hydrochloride Tablets in US over excessive NDMA level
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.